Abstract
The topical delivery of bromelain as an anti-inflammatory solution for skin inflammation has attracted the attention of researchers. Due to the skin barrier issue, a new method was designed for the effective delivery of specific doses of bromelain to the desired action sites. A niosome was selected as a novel and practical transdermal vehicle for the delivery of bromelain to inflamed sites. In this regard, a lipopolysaccharide (LPS)-induced human skin fibroblast (HSF1184) cell line was assembled in-vitro as a simulated model. The levels of interleukin-6 (IL-6) and tumour necrosis factor alpha (TNF-α), the two immune-modulatory regulators of cell responses to inflammation, were measured to determine the response towards the niosome-encapsulated bromelain treatment. The results showed that the niosome-encapsulated bromelain significantly reduced the levels of IL-6 and TNF-α compared to the non-encapsulated bromelain, the vehicle (niosome) and the control.
Highlights
Bromelain has demonstrated many beneficial properties in-vitro and invivo such as anti-oedematous, anti-thrombotic, and fibrinolytic properties
Among the secreted regulators of inflammation that are connected to the NF-kB pathways and that respond to bromelain are IFN-γ, TNF-α, IL-1β, and IL-6
Experimental evidence derived from an analysis of peripheral blood mononuclear cells (PBMC) from healthy volunteers as well as mouse macrophages suggest that bromelain can activate TNF-α, IL-1β and IL-6 secretions in an IFN-γ-dependent mechanism [14,15]
Summary
Bromelain has demonstrated many beneficial properties in-vitro and invivo such as anti-oedematous, anti-thrombotic, and fibrinolytic properties. The described data demonstrate that the effects of bromelain on cytokine expressions depend on the presence of inflammation-inducing conditions. This underlines the potential of bromelain for the treatment of inflammation-based pathologies. Niosome-encapsulated bromelain was shown to be an effective compound that reduces the levels of IL-6 and TNF-α in LPS-induced inflammation of the human skin fibroblast (HSF1184) cell line. This is the first study to use niosome-encapsulated bromelain as an anti-inflammatory application. The inflammation responses were measured after four hours and 24hours
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
